{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:33:07Z","timestamp":1786984387596,"version":"build-2736575974"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","award":["I8-TSA-021"],"award-info":[{"award-number":["I8-TSA-021"]}],"id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Union 7th Framework Program EUVIRNA Marie Curie Initial Training Network","award":["264286"],"award-info":[{"award-number":["264286"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.antiviral.2014.07.003","type":"journal-article","created":{"date-parts":[[2014,7,17]],"date-time":"2014-07-17T13:16:47Z","timestamp":1405603007000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["H1PVAT is a novel and potent early-stage inhibitor of poliovirus replication that targets VP1"],"prefix":"10.1016","volume":"110","author":[{"given":"Aloys","family":"Tijsma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik Jan","family":"Thibaut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane A.H.","family":"Spieser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"De Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Koukni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Rhoden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Oberste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"P\u00fcrstinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia","family":"Volny-Luraghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Marchand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Chaltin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Neyts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Leyssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2014.07.003_b0015","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/BF01310997","article-title":"In vitro activity of R 61837, a new antirhinovirus compound","volume":"101","author":"Andries","year":"1988","journal-title":"Arch. Virol."},{"key":"10.1016\/j.antiviral.2014.07.003_b0020","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/BF01311037","article-title":"Lack of quantitative correlation between inhibition of replication of rhinoviruses by an antiviral drug and their stabilization","volume":"106","author":"Andries","year":"1989","journal-title":"Arch. Virol."},{"key":"10.1016\/j.antiviral.2014.07.003_b0165","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1128\/AAC.36.1.100","article-title":"In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity","volume":"36","author":"Andries","year":"1992","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.07.003_b0030","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00705-010-0895-6","article-title":"The frequency and biodiversity of poliovirus and non-polio enterovirus strains isolated from healthy children living in a limited area in Romania","volume":"156","author":"Baicus","year":"2011","journal-title":"Arch. Virol."},{"key":"10.1016\/j.antiviral.2014.07.003_b0035","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1128\/AAC.41.6.1220","article-title":"SCH 48973: a potent, broad-spectrum, antienterovirus compound","volume":"41","author":"Buontempo","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.07.003_b0040","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.antiviral.2008.04.002","article-title":"A case for developing antiviral drugs against polio","volume":"79","author":"Collett","year":"2008","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2014.07.003_b0045","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1021\/cc049855o","article-title":"Liquid-phase synthesis of combinatorial libraries based on 7-trifluoromethyl-substituted pyrazolo[1,5-a]pyrimidine scaffold","volume":"7","author":"Dalinger","year":"2005","journal-title":"J. Comb. Chem."},{"key":"10.1016\/j.antiviral.2014.07.003_b0050","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/S0140-6736(13)62220-5","article-title":"Polio emergence in Syria and Israel endangers Europe","volume":"382","author":"Eichner","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2014.07.003_b0010","unstructured":"EU Clinical Trials Register. 2013. 2011\u2013004804-38."},{"key":"10.1016\/j.antiviral.2014.07.003_b0055","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1128\/AAC.30.1.110","article-title":"Prevention of rhinovirus and poliovirus uncoating by WIN 51711, a new antiviral drug","volume":"30","author":"Fox","year":"1986","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.07.003_b0060","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/S0960-9822(00)00176-7","article-title":"Structures of poliovirus complexes with anti-viral drugs: implications for viral stability and drug design","volume":"4","author":"Grant","year":"1994","journal-title":"Curr. Biol."},{"key":"10.1016\/j.antiviral.2014.07.003_b0170","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1107\/S0907444997000954","article-title":"Ligand-induced conformational changes in poliovirus-antiviral drug complexes","volume":"53","author":"Hiremath","year":"1997","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.antiviral.2014.07.003_b0070","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0378-1119(89)90358-2","article-title":"Site-directed mutagenesis by overlap extension using the polymerase chain reaction","volume":"77","author":"Ho","year":"1989","journal-title":"Gene"},{"key":"10.1016\/j.antiviral.2014.07.003_b0075","doi-asserted-by":"crossref","first-page":"999","DOI":"10.3851\/IMP1838","article-title":"Immunological and pathogenic properties of poliovirus variants selected for resistance to antiviral drug V-073","volume":"16","author":"Kouiavskaia","year":"2011","journal-title":"Antiviral Ther."},{"key":"10.1016\/j.antiviral.2014.07.003_b0080","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0969-2126(97)00249-9","article-title":"Structure of poliovirus type 2 Lansing complexed with antiviral agent SCH48973: comparison of the structural and biological properties of three poliovirus serotypes","volume":"5","author":"Lentz","year":"1997","journal-title":"Structure"},{"key":"10.1016\/j.antiviral.2014.07.003_b0175","doi-asserted-by":"crossref","first-page":"5568","DOI":"10.1128\/AAC.00539-12","article-title":"Characterization of poliovirus variants selected for resistance to the antiviral compound V-073","volume":"56","author":"Liu","year":"2012","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/j.antiviral.2014.07.003_b0090","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/S0140-6736(04)16150-3","article-title":"Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man","volume":"363","author":"MacLennan","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2014.07.003_b0095","doi-asserted-by":"crossref","first-page":"7601","DOI":"10.1128\/JVI.69.12.7601-7605.1995","article-title":"Role of mutations G-480 and C-6203 in the attenuation phenotype of Sabin type 1 poliovirus","volume":"69","author":"McGoldrick","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.07.003_b0100","doi-asserted-by":"crossref","first-page":"8193","DOI":"10.1128\/JVI.68.12.8193-8201.1994","article-title":"Distribution of drug resistance mutations in type 3 poliovirus identifies three regions involved in uncoating functions","volume":"68","author":"Mosser","year":"1994","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.07.003_b0105","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1128\/JVI.73.3.1941-1948.1999","article-title":"Molecular evolution of the human enteroviruses: correlation of serotype with VP1 sequence and application to picornavirus classification","volume":"73","author":"Oberste","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.07.003_b0110","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.antiviral.2013.03.003","article-title":"Anti-poliovirus activity of protease inhibitor AG-7404, and assessment of in vitro activity in combination with antiviral capsid inhibitor compounds","volume":"98","author":"Rhoden","year":"2013","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2014.07.003_b0115","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1126\/science.342.6159.679","article-title":"Infectious disease. Israel\u2019s silent polio epidemic breaks all the rules","volume":"342","author":"Roberts","year":"2013","journal-title":"Science"},{"issue":"Pt 9","key":"10.1016\/j.antiviral.2014.07.003_b0120","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1099\/0022-1317-72-9-2153","article-title":"A comparison of WIN 51711 and R 78206 as stabilizers of poliovirus virions and procapsids","volume":"72","author":"Rombaut","year":"1991","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.antiviral.2014.07.003_b0125","first-page":"173","article-title":"Stabilisation of poliovirus with pirodavir","volume":"87","author":"Rombaut","year":"1996","journal-title":"Dev. Biol. Stand."},{"key":"10.1016\/j.antiviral.2014.07.003_b0130","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1128\/AAC.48.6.2233-2243.2004","article-title":"Mechanism of action at the molecular level of the antiviral drug 3(2H)-isoflavene against type 2 poliovirus","volume":"48","author":"Salvati","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2014.07.003_b0005","unstructured":"Schr\u00f6dinger Suite, 2012. 3-10-0012. Schr\u00f6dinger, LLC, New York, NY. Ref Type: Computer Program."},{"key":"10.1016\/j.antiviral.2014.07.003_b0135","doi-asserted-by":"crossref","first-page":"8693","DOI":"10.1128\/JVI.02388-08","article-title":"Shedding of vaccine viruses with increased antigenic and genetic divergence after vaccination of newborns with monovalent type 1 oral poliovirus vaccine","volume":"83","author":"van der Sanden","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.07.003_b0140","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1128\/JVI.62.2.558-562.1988","article-title":"Direct measurement of the poliovirus RNA polymerase error frequency in vitro","volume":"62","author":"Ward","year":"1988","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.07.003_b0145","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1021\/jm0202876","article-title":"An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus","volume":"46","author":"Watson","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.antiviral.2014.07.003_b0180","series-title":"Report of the interim meeting of the Technical Consultative Group (TCG) on the Global Eradication of Poliomyelitis. WHO\/V&B\/30.04","author":"World Health Organization","year":"2002"},{"key":"10.1016\/j.antiviral.2014.07.003_b0155","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1128\/JVI.80.6.2641-2653.2006","article-title":"Antigenic evolution of vaccine-derived polioviruses: changes in individual epitopes and relative stability of the overall immunological properties","volume":"80","author":"Yakovenko","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2014.07.003_b0160","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1056\/NEJM197905243002102","article-title":"Isolation of a virus from the pancreas of a child with diabetic ketoacidosis","volume":"300","author":"Yoon","year":"1979","journal-title":"N. Engl. J. Med."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354214002022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354214002022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T06:36:04Z","timestamp":1598078164000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354214002022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":32,"alternative-id":["S0166354214002022"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2014.07.003","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"H1PVAT is a novel and potent early-stage inhibitor of poliovirus replication that targets VP1","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2014.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}